Drug Information

Drug General Information
Drug ID
D01ZII
Former ID
DAP000374
Drug Name
Chlorpromazine
Synonyms
Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromazin; Chlorpromazinum; Clorpromazina; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Largactil; Largactilothiazine; Largactyl; Megaphen; Novomazina; Phenactyl; Phenathyl; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; Sanopron; Thorazine; Torazina; Wintermin; Chlorpromazine Tannate; Clorpromazina [Italian]; Fraction AB; Largactil Liquid; Largactil Oral Drops; Phenothiazine hydrochloride; Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; BC 135; HL 5746; JHICC02042; SKF 2601A; Z80; Chlor-PZ; Chlor-Promanyl; Chlorpromanyl (discontinued); Chlorpromazinum [INN-Latin]; Clorpromazina [INN-Spanish]; Largactil (TN); Novo-Chlorpromazine; SKF 2601-A; SKF-2601; Thorazine (TN); Chlorpromazine (USP/INN); Chlorpromazine [USAN:INN:BAN]; Chloro-3 (dimethylamino-3 propyl)-10 phenothiazine; Chloro-3 (dimethylamino-3 propyl)-10 phenothiazine [French]; N-(3-Dimethylaminopropyl)-3-chlorophenothiazine; [3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine; 10-(3-Dimethylaminopropyl)-2-chlorophenothiazine; 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-, radical ion(1+); 2-Chloro-10-(3-(dimethylamino)propyl)phenothiazine; 2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine; 2-Chloropromazine; 2-Cloro-10 (3-dimetilaminopropil)fenotiazina; 2-Cloro-10 (3-dimetilaminopropil)fenotiazina [Italian]; 2-chloro-10-(3-(dimethylamino)propyl)-phenothiazine; 2-chloro-N,N-dimethyl-10H-Phenothiazine-10-propanamine; 3-(2-Chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine; 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine; 3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine; 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine
Drug Type
Small molecular drug
Indication Schizophrenia [ICD9: 295; ICD10:F20] Approved [538339], [543051]
Therapeutic Class
Antipsychotic Agents
Company
GlaxoSmithKline
Structure
Download
2D MOL

3D MOL
Formula
C17H19ClN2S
InChI
InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
InChIKey
ZPEIMTDSQAKGNT-UHFFFAOYSA-N
CAS Number
CAS 50-53-3
PubChem Compound ID
2726
PubChem Substance ID
9123, 441206, 602724, 841999, 4332427, 7847336, 7978926, 8149253, 8151764, 10524433, 10588932, 11110990, 11110991, 11120337, 11120825, 11121313, 11335799, 11361038, 11363036, 11364725, 11365598, 11367287, 11368160, 11369849, 11371331, 11372890, 11373945, 11375449, 11376322, 11378013, 11462010, 11466092, 11467212, 11484847, 11485904, 11488972, 11490162, 11492098, 11493956, 12014508, 14923746, 24398080, 25688547, 26611657, 26680205, 26747094, 26747095, 26751620, 26751621, 29221882
ChEBI ID
ChEBI:3647
SuperDrug ATC ID
N05AA01
SuperDrug CAS ID
cas=000050533
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Antagonist [537110], [537239], [538131]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 538339FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 080439.
Ref 543051(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 83).
Ref 537110Basolateral amygdala D1- and D2-dopaminergic system promotes the formation of long-term potentiation in the dentate gyrus of anesthetized rats. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):552-6. Epub 2009 Feb 23.
Ref 537239Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral amygdala-dentate gyrus pathway of anesthetized rats. Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3. Epub 2009 Jan 22.
Ref 538131Behavioral and neurochemical methods in research on new psychotropics. Ann Pharm Fr. 1998;56(2):54-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.